The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
It’s good to see goldstone have got ~1500oz produced. Looking forward to some progress in Jan/Feb after the disappointing recovery rate issues:
-Pad 3 stacking
-Updated DEP
-Reviewed production schedule
- Drilling Akrokeri to start
Crossed fingers for 2022
Yeah bishop has done this before. Tries to take the heat off being outed as one of the scumbags on here. Likely wyndrum….then resurfaces after cleaning up a few of the libellous tweets (forgetting screenshots don’t dissaperar). He’ll be back.
As for the king of the dividend Touk….get some nee material, you were spouting this months and months ago. It’s been made clear no dividends. The company has a lot to be funding.
Bishop will have a libel case at some point anyway - that’ll shut him/her up. Claimed
- Avacta had ended M19 relationship
- Ava6000 paused
- Jupiter bought AffiDx and tested it, saw it failed and took out a short (before omicron was even a thing)
Imaginative chap - just thick as two short planks!
https://twitter.com/GoldstoneRes/status/1481582566637457408
So that's 37Kg of gold. Which will cover the loan payments until Feb (including feb). So I am hoping that gives them the time to sort the agglomeration issues out
A good piece Mr Blue. I am of the opinion we will see the MRE2 in the NCM December quarterly report (due 28th Jan)
Couple of weeks to see:
-What Zipa and Hav North holes contained
-Get an updated MRE (hopefully)
-Results for what will be all growth drilling on SE crescent as all infill completed plus other areas growth drilling
All of which should give even further clarity on what we are looking at here with HAV.
Despite the depressing SP I am looking forward to the next update.
MIKODX - This is actually an interesting read on Abingdon website about how LFT's work.
https://www.abingdonhealth.com/services/what-is-lateral-flow-immunoassay/
Couple of quotes:
"LFDs use immunoassay technology using nitrocellulose membrane, coloured nanoparticles (or labels), and typically antibodies, to produce results."
"The conjugate pad, which stores the conjugated labels and antibodies, will receive the sample. If the target is present, the immobilised conjugated antibodies and labels will bind to the target and continue to migrate along the test."
Ties with the IFU info so not sure you can call BS there, it's probably more a case of LFT's being more complex than many think.
Just popped it in bold for you Regulator - trip to the opticians this weekend maybe?
"The sample buffer provided in the buffer capsule is dispensed
into the swab extraction tube. An anterior nasal swab sample
is collected from the patient using the swab provided, which
is then placed into the swab extraction tube and the tip of
the swab is snapped off, leaving the swab tip in the swab
extraction tube. This is then mixed, lysing the virus and
releasing the SARS-CoV-2 antigen into the sample buffer.
The sample buffer is added to the sample well on the lateral
flow device, using the nozzle on the swab extraction tube.
If SARS-CoV-2 antigen is present in the patient sample this
will bind to biotinylated Affimer® binders highly specific to
SARS-CoV-2 antigen. This antigen-Affimer® complex is then in
turn specifically bound to conjugated microparticles, with the
antigen-Affimer®-microparticle complex migrating along the
lateral flow strip by capillary action until it reaches the test line.
Immobilised poly-streptavidin is present on the test line which
binds the complex via the available biotin label on the Affimer®
binder. Remaining unbound microparticles continue to migrate
along the lateral flow strip until they reach the control line, where
they are captured by an immobilised ANTIBODY specific to the
conjugated microparticles. The test result is then read by visual
determination of the presence or absence of a band at the test
line in conjunction with the presence of a band at the control line."
It's also noted in the product's IFU
https://bioservuk.com/wp-content/uploads/2021/06/IFU.pdf
"The sample buffer provided in the buffer capsule is dispensed
into the swab extraction tube. An anterior nasal swab sample
is collected from the patient using the swab provided, which
is then placed into the swab extraction tube and the tip of
the swab is snapped off, leaving the swab tip in the swab
extraction tube. This is then mixed, lysing the virus and
releasing the SARS-CoV-2 antigen into the sample buffer.
The sample buffer is added to the sample well on the lateral
flow device, using the nozzle on the swab extraction tube.
If SARS-CoV-2 antigen is present in the patient sample this
will bind to biotinylated Affimer® binders highly specific to
SARS-CoV-2 antigen. This antigen-Affimer® complex is then in
turn specifically bound to conjugated microparticles, with the
antigen-Affimer®-microparticle complex migrating along the
lateral flow strip by capillary action until it reaches the test line.
Immobilised poly-streptavidin is present on the test line which
binds the complex via the available biotin label on the Affimer®
binder. Remaining unbound microparticles continue to migrate
along the lateral flow strip until they reach the control line, where
they are captured by an immobilised antibody specific to the
conjugated microparticles. The test result is then read by visual
determination of the presence or absence of a band at the test
line in conjunction with the presence of a band at the control line."
Regulator - 2nd Nov RNS - READ IT
"The impact of suspension of sales in the UK as a result of the CTDA regulations coming into force will not have a material impact on the Company's anticipated financial outturn for the financial year ending 31 December 2021. As previously noted, Avacta continues to focus on opportunities outside of the UK for the sale and marketing of its AffiDX SARS-CoV-2 Lateral Flow Rapid Antigen Test including markets in Europe and further afield. "
What does that tell you about Avacta's focus on UK market?
Half the public have no idea how carp the Chinese tests are - so why would they buy them when they get them for free (if you can get hold of them).
The UK market is not where the value lies - Avacta made it clear. This approval opens up Europe. APAC approvals Due Q4.
They are the hot markets
Zoom - just in time for the Agile launch
Abingdon seem confident enough in the test to include “Technical transfer anticipated to conclude this year” in a recent RNS.
https://agiletestservices.com/collections/all
Arf arf arf….roll up roll up for the wyndrum show.
The two shorting strategies have been openly described by the companies themselves as shorts on the small cap sector, not Avacta.
So as long as the SP here remains range bound and AIM in general continues its dismal year they have nothing to worry about.
The problem is, they won’t have done in depth analysis on each stock. A number of near term catalysts here could burn them pretty quickly!
Well that escalated quickly...great news, account deleted!
https://twitter.com/Bishop5022
Agreed I have a couple and have sent over too to Avacta asking for it to be addressed.
Either he's in possession of material non public info (very unlikely) or trying to spread misinformation to impact the share price....be in trouble for either
If you're looking at EBITDA then what you have calculated seems sensible - the P/E ratio sounds sensible but the range of P/E's in this industry make it hard to pinpoint a target.
Corporation tax is 35% in Ghana for mining companies (10% higher than standard rate). There is also a 5% mining royalty on revenues.....something extra to consider when looking at bottom line profits coming back into the business
Not sure on that wonga….I think AS is bullish near term on therapeutics because that it’s almost fully in the hands of Avacta. All deadlines have bit hit ahead on that front.
I don’t think diagnostics is going to struggle by any means - IMO AS is now being overly cautious with messaging on that front given Avactas work is done and this is all now in the hands of notified bodies/regulators. Could be a week could be a month….he has no control over that so why be overly bullish